Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MR contrast agents in lymph node imaging.

Bernd Misselwitz1

  • 1Research Laboratories of Schering AG, CRBA Diagnostics and Radiopharmaceuticals, MRI and X-Ray Research, Müllerstrasse 178, D-13342 Berlin, Germany. bernd.misselwitz@schering.de

European Journal of Radiology
|February 9, 2006
PubMed
Summary

Detecting cancer spread to lymph nodes is crucial. A new contrast agent, Gadofluorine M, allows for early detection of lymph node metastases within 60 minutes after intravenous injection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MR imaging features of gadofluorine-labeled matrix-associated stem cell implants in cartilage defects.

PloS one·2012
Same author

Gadofluorine M-enhanced magnetic resonance imaging of inflammatory bowel disease: quantitative analysis and histologic correlation in a rat model.

Investigative radiology·2011
Same author

Gadofosveset-enhanced magnetic resonance imaging of human carotid atherosclerotic plaques: a proof-of-concept study.

Investigative radiology·2010
Same author

Roles of myocardial blood volume and flow in coronary artery disease: an experimental MRI study at rest and during hyperemia.

European radiology·2010
Same author

Evaluation of rHA labeled with Gd-DTPA for blood pool imaging and targeted contrast delivery.

Contrast media & molecular imaging·2010
Same author

Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography.

Circulation. Cardiovascular imaging·2009

Area of Science:

  • Oncology
  • Radiology
  • Medical Imaging

Background:

  • Accurate detection of tumor metastases in lymph nodes is vital for cancer staging and treatment planning.
  • Current imaging techniques struggle to differentiate malignant from benign lymph nodes based solely on size and shape, potentially missing small metastases or misdiagnosing enlarged nodes.
  • A specific lymphotropic contrast agent is required to enhance contrast between functional and metastatic lymph node tissues.

Purpose of the Study:

  • To evaluate the efficacy of a novel gadolinium-type contrast agent, Gadofluorine M, for detecting lymph node metastases.
  • To determine the time frame for achieving sufficient contrast for metastasis detection after intravenous administration.
  • To address the limitations of existing contrast agents in MR lymphography.

Main Methods:

Related Experiment Videos

  • Contrast-enhanced MR lymphography was employed.
  • Gadofluorine M, a gadolinium-type contrast agent, was administered intravenously.
  • The detection of lymph node metastases was assessed within 60 minutes post-injection.

Main Results:

  • Gadofluorine M demonstrated the ability to detect lymph node metastases.
  • Sufficient contrast for metastasis detection was achieved within 60 minutes of intravenous injection.
  • This represents a significant improvement over existing agents like ultrasmall superparamagnetic iron oxide particles, which require 24 hours.

Conclusions:

  • Gadofluorine M is a promising lymphotropic contrast agent for MR lymphography.
  • It enables rapid and effective detection of lymph node metastases, improving upon current diagnostic capabilities.
  • This advancement can aid in more accurate tumor staging and personalized therapy planning for cancer patients.